Featured Research

from universities, journals, and other organizations

Vaccine confers long-term protection against cholera

Date:
October 16, 2013
Source:
International Vaccine Institute
Summary:
A clinical study shows for the first time that an oral cholera vaccine (ShancholTM) provides sustained protection against cholera in humans for up to five years. The study showed the vaccine had a protective efficacy of 65 percent over a five-year period.

A clinical study published in the Lancet Infectious Diseases shows for the first time that an oral cholera vaccine (ShancholTM) provides sustained protection against cholera in humans for up to five years. The study showed the vaccine had a protective efficacy of 65% over a five-year period. The landmark study was a collaboration between scientists from the International Vaccine Institute (IVI) an international organization based in Seoul, and the National Institute of Cholera and Enteric Diseases, (NICED), an institute under the Indian Council of Medical Research (ICMR) of India's Ministry of Health and Family Welfare.

Cholera is a potentially deadly infectious disease that causes profuse, dehydrating diarrhea in children and adults. It is spread through ingestion of contaminated water or food and is commonly found in developing countries that have limited access to clean water and sanitation. There are about 2.8 million cases and 91,000 deaths each year from cholera, mostly in Africa and South Asia.

The oral cholera vaccine (OCV) contains strains of killed cholera bacteria that have been previously shown to be safe in humans and is administered through a two-dose regimen. The vaccine was specifically developed for use in developing countries through a public-private partnership led by IVI with support from the Republic of Korea, Sweden, and the Bill & Melinda Gates Foundation. The partnership involved Shantha Biotechnics (part of the Sanofi group) based in Hyderabad, India; VaBiotech, a state-owned vaccine manufacturer located in Hanoi, Vietnam; and the University of Gothenburg in Sweden. The vaccine, which is produced by Shantha Biotechnics in India and licensed as Shanchol™, was prequalified by the World Health Organization (WHO) in September 2011.

A Phase III clinical trial was jointly conducted by IVI and NICED in Kolkata, India in 2006 to assess the efficacy of the vaccine. More than 30,000 volunteers from one year old and up were enrolled in the study. A placebo group with a similar number of volunteers was also included.

Previous results from this study had shown that the vaccine provided 66% protection over a three-year period, and the new result shows that such protection is sustained for two additional years. Since vaccine protection does not wane over time, the study has important practical implications in terms of vaccination cost and vaccination strategies in developing countries.

"The study results suggest that this vaccine will protect persons at risk of severe cholera for five years," said Dr. Thomas F. Wierzba, Deputy Director General of Vaccine Development & Delivery at IVI and co-author of the study. "With protection sustained for five years, we will be able to provide greater benefits to the poor at reduced costs."

Furthermore, the study confirms the use of the vaccine as a powerful and effective tool to prevent and control cholera. "The vaccine is safe, easy to administer, cost effective, and provides protection for up to five years," said Dr. Christian Loucq, IVI's Director General. "The use of the vaccine, combined with other control measures, will make it more feasible for developing countries afflicted by cholera to control a disease that plagues millions of people every year."

The vaccine has already been used to combat outbreaks in Haiti and Guinea, and has been deployed for large-scale use in Bangladesh and Odisha state, India.


Story Source:

The above story is based on materials provided by International Vaccine Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sujit K Bhattacharya, Dipika Sur, Mohammad Ali, Suman Kanungo, Young Ae You, Byomkesh Manna, Binod Sah, Swapan K Niyogi, Jin Kyung Park, Banwarilal Sarkar, Mahesh K Puri, Deok Ryun Kim, Jacqueline L Deen, Jan Holmgren, Rodney Carbis, Mandeep Singh Dhingra, Allan Donner, G Balakrish Nair, Anna Lena Lopez, Thomas F Wierzba, John D Clemens. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases, 2013; DOI: 10.1016/S1473-3099(13)70273-1

Cite This Page:

International Vaccine Institute. "Vaccine confers long-term protection against cholera." ScienceDaily. ScienceDaily, 16 October 2013. <www.sciencedaily.com/releases/2013/10/131016213048.htm>.
International Vaccine Institute. (2013, October 16). Vaccine confers long-term protection against cholera. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/10/131016213048.htm
International Vaccine Institute. "Vaccine confers long-term protection against cholera." ScienceDaily. www.sciencedaily.com/releases/2013/10/131016213048.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins